ADAP vs. BDTX, AVXL, MGTX, GLUE, IVVD, MGX, CRBU, PGEN, SOPH, and AGEN
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Black Diamond Therapeutics (BDTX), Anavex Life Sciences (AVXL), MeiraGTx (MGTX), Monte Rosa Therapeutics (GLUE), Invivyd (IVVD), Metagenomi (MGX), Caribou Biosciences (CRBU), Precigen (PGEN), SOPHiA GENETICS (SOPH), and Agenus (AGEN). These companies are all part of the "medical" sector.
Adaptimmune Therapeutics (NASDAQ:ADAP) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability.
In the previous week, Adaptimmune Therapeutics had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 1 mentions for Adaptimmune Therapeutics and 0 mentions for Black Diamond Therapeutics. Adaptimmune Therapeutics' average media sentiment score of 0.97 beat Black Diamond Therapeutics' score of 0.00 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media.
Adaptimmune Therapeutics has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.56, meaning that its share price is 156% more volatile than the S&P 500.
Adaptimmune Therapeutics currently has a consensus price target of $2.50, indicating a potential upside of 138.10%. Black Diamond Therapeutics has a consensus price target of $12.25, indicating a potential upside of 72.78%. Given Adaptimmune Therapeutics' higher probable upside, equities research analysts plainly believe Adaptimmune Therapeutics is more favorable than Black Diamond Therapeutics.
Black Diamond Therapeutics has lower revenue, but higher earnings than Adaptimmune Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
Adaptimmune Therapeutics received 269 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 63.33% of users gave Black Diamond Therapeutics an outperform vote while only 62.53% of users gave Adaptimmune Therapeutics an outperform vote.
31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Black Diamond Therapeutics has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -188.90%. Black Diamond Therapeutics' return on equity of -76.43% beat Adaptimmune Therapeutics' return on equity.
Summary
Adaptimmune Therapeutics beats Black Diamond Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
